Two weeks ago, a drop in Gilead Sciences Inc. (NASDAQ:GILD) stock, after U.S. lawmakers asked it to explain the $84,000 price tag of its new hepatitis C drug Sovaldi, set off a wave of losses in other biotech and momentum names. Gilead Sciences, Inc. (NASDAQ:GILD) shares after opening at $74.91 moved to $75.25 on last trade day and at the end of the day closed at $72.20. Company price to sales ratio in past twelve months was calculated as 9.91 and price to cash ratio as 52.09. Gilead Sciences, Inc. (NASDAQ:GILD) showed a positive weekly performance of 5.32%.
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced the appointment of Hugh M. Cole to the position of senior vice president and chief business officer. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares fell -2.45% in last trading session and ended the day on $7.58. ARIA return on equity ratio is recorded as -98.50% and its return on assets is -65.80%. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) yearly performance is -55.09%.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) recognized revenues of $81.4 million for the year ended December 31, 2013, compared to $27.6 million for the year ended December 31, 2012. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares moved down -3.12% in last trading session and was closed at $6.22, while trading in range of $6.11 – $6.59. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) year to date (YTD) performance is 6.32%.
Among the biggest gainers was MannKind Corp. (NASDAQ:MNKD) in last trading session. A Food and Drug Administration advisory panel recommended the agency approve the Valencia biotech’s Afrezza inhalable insulin device despite some concerns about side-effects. MannKind Corporation (NASDAQ:MNKD) weekly performance is 42.24%. On last trading day company shares ended up $6.87. MannKind Corporation (NASDAQ:MNKD) distance from 50-day simple moving average (SMA50) is 21.19%. Analysts mean target price for the company is $7.07.
Leave a Reply